Karen Reckamp, Barbara Gitlitz, Lin-Chi Chen, Ravi Patel, Ginger Milne, Mary Syto, Deborah Jezior and Sara Zaknoen Biomarker-based phase I dose-escalation, pharmacokinetic, and pharmacodynamic study of oral apricoxib in combination with erlotinib in advanced nonsmall cell lung cancer Cancer 117
Article first published online: 4 OCT 2010 | DOI: 10.1002/cncr.25473
Twenty patients with stage IIIB/IV nonsmall cell lung cancer were treated with apricoxib, a novel cyclooxygenase-2 inhibitor (100, 200, or 400 mg/day), in combination with 150 mg/day erlotinib. Treatment was well tolerated and associated with a 60% disease control rate and greater antitumor activity in patients with a decrease from baseline prostaglandin E2 metabolite (PGE-M). Therefore, 400 mg/day apricoxib plus 150 mg/day erlotinib is being investigated in a phase II study in patients selected based on change in urinary PGE-M.
Complete the form below and we will send an e-mail message containing a link to the selected article on your behalf
Required = Required Field